Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging SV2A in Mood Disorders
NCT02734602Active, not recruiting
- Sponsor
- Yale University
- Start
- Apr 2016
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ketamine in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (3 arms), sponsored by Yale University. Primary endpoints: Evidence of synaptic changes in psychiatric disorders confirmed by PET data at 5 years and Evidence of synaptic density at time of its greatest anti-depressant response in psychiatric disorders confirmed with PET data at 5 years. Started Apr 2016; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT02734602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02734602.